> It seems that hardly a week goes by in which Emergent Biosolutions doesn't get a vaccine contract. This week it's a $404 million contract with the U.S. government to provide 14.5 million doses of BioThrax anthrax vaccine. Vaccine report
> Citing economic concerns and the overstock of flu vaccines in the U.S., Solvay announced that it won't proceed with a planned $300 million flu vaccine plant originally slated to open in Alabama. Report
> Big Pharma companies have a lot of cash on hand, which the Motley Fool says will contribute to more M&A. Report
> The FDA has approved a third indication for Eli Lilly's cancer drug, Alimta. The agency approved Altima for use in combination with cisplatin to treat patients with non-small cell lung cancer and will be a first-line treatment for patients with locally advanced and metastatic lung cancer with nonsquamous histology. Report
> The media are not great watchdogs of big pharma it turns out, but pharma companies will likely see a sea change in reporting about drug studies in the future. Article
> A new stem cell insertion method discovered by Harvard researchers eliminates cancer risk. Report
> A new Danish study involving nearly 700,000 women showed that hormone replacement therapy might not put women at increased risk of heart disease, after all. Report
> Johnson and Johnson received some happy news yesterday when a federal judge awarded its cardiac device unit $1.2 billion in a longstanding battle between the megacompany, Boston Scientific and Medtronic over a stent device. Report
Industry Voices: How to get the most out of your CRO. Article
And Finally... Pfizer is steadily expanding its presence in the stem cell field. The Wall Street Journal notes that in November the pharma giant will open a regenerative medicine shop in Cambridge, England. Report